Bolt Biotherapeutics(BOLT)

Focus: Bolt Biotherapeutics is a public-stage biotechnology company focused on systemically delivered Immune-Stimulating Antibody Conjugates (ISACs) for oncology. The company is headquartered in Redwood City, CA and operates as a clinical-stage biotech with no approved products.

Oncology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Bolt Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Bolt Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$8M

Pipeline & Clinical Trials

BDC-3042

Triple Negative Breast Cancer

PHASE_1

Clinical Trials (1)

NCT06052852Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1

Help build intelligence for Bolt Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering platform technology (ISACs) in high-unmet-need oncology space with differentiated mechanism targeting systemic immunity
Public company status provides liquidity, visibility, and potential equity upside alongside early-stage innovation exposure
Multi-indication pipeline across breast cancer and gastric cancer with ongoing Phase 1/2 clinical studies generating near-term data readouts

Watch Out For

Severe cash burn ($63M net loss FY2025) against minimal revenue ($8M) and rapidly depleting cash reserves ($7M) signals potential financing distress within 12 months
No Phase 3 programs, zero active job openings, and extreme R&D intensity (747%) indicate either organizational contraction or intense focus that limits hiring and career mobility
Pre-commercial stage with single-digit clinical trial footprint creates execution risk and limited near-term product validation

Generated by Claude from Bolt Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

BDC-4182

Gastric Cancer Adenocarcinoma Metastatic

PHASE_1_2

Clinical Trials (1)

NCT06921837A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Phase 1/2

BDC-1001

HER2-positive Solid Tumors

PHASE_1_2

BDC-1001

Metastatic Breast Cancer

PHASE_2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$8M2%

R&D Spend

$57M(747%)7%

Net Income

-$63M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

WARN Act Layoff Notices (1)

2024-05-14

38 employees affected— CA

source

Source: state DOL filings, aggregated via Big Local News

No immediate regulatory red flags detected, but financial trajectory suggests heightened operational risk within next 6-12 months.